Seizure characteristics and prognostic factors of gliomas

Epilepsia

Volumn 54, Issue SUPPL. 9, 2013, Pages 12-17

  Kerkhof, Melissa ^a   Vecht, Charles J ^a,b  

^a Medical Center the Hague   (Netherlands)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Epilepsy; Gliomas; Neuroglial tumors; Prognostic factors; Seizure characteristics; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; VALPROIC ACID;

BRAIN TUMOR; CLASSIFICATION; EPILEPSY; GLIOMA; GLIOMAS; HUMAN; NEUROGLIAL TUMORS; PROGNOSTIC FACTORS; REVIEW; SEIZURE; SEIZURE CHARACTERISTICS; COMPLICATION; SEIZURES;

EPILEPSY; GLIOMAS; NEUROGLIAL TUMORS; PROGNOSTIC FACTORS; SEIZURE CHARACTERISTICS; VALPROIC ACID;

ANTICONVULSANTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; SEIZURES;

EID: 84894308669     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12437     Document Type: Article

References (25)

1. Blumcke I, Wiestler OD. (2002) Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 61:575-584.
2. Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H. (2013) Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg 118:1157-1168.
3. Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A. (2009) Longterm seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 111:282-292.
4. Chandrashekhar TN, Mahadevan A, Vani S, Yasha TC, Sampath S, Chandramouli BA, Devi BI, Arvinda HR, Shankar SK. (2012) Pathological spectrum of neuronal/glioneuronal tumors from a tertiary referral neurological Institute. Neuropathology 32:1-12.
5. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS. (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227-235.
6. Compton JJ, Laack NN, Eckel LJ, Schomas DA, Giannini C, Meyer FB. (2012) Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic. J Neurosurg 117:825-830.
7. Englot DJ, Berger MS, Barbaro NM, Chang EF. (2011) Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg 115:240-244.
8. Englot DJ, Berger MS, Barbaro NM, Chang EF. (2012) Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia 53:51-57.
9. Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ. (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961-967.
10. Majchrzak K, Kaspera W, Bobek-Billewicz B, Hebda A, Stasik-Pres G, Majchrzak H, Ladzinski P. (2012) The assessment of prognostic factors in surgical treatment of low-grade gliomas: a prospective study. Clin Neurol Neurosurg 114:1135-1144.
11. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M. (2008) Tumor recurrence and malignant progression of gangliogliomas. Cancer 113:3355-3363.
12. Rosati A, Poliani PL, Todeschini A, Cominelli M, Medicina D, Cenzato M, Simoncini EL, Magrini SM, Buglione M, Grisanti S, Padovani A. (2013) Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol 15:618-625.
13. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El HS, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY. (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154.
14. Smits A, Duffau H. (2011) Seizures and the natural history of World Health Organization Grade II gliomas: A review. Neurosurgery 68:1326-1333.
15. Southwell DG, Garcia PA, Berger MS, Barbaro NM, Chang EF. (2012) Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 70:1406-1413; discussion 13-4.
16. Stockhammer F, Misch M, Helms HJ, Lengler U, Prall F, von DA, Hartmann C. (2012) IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 21:194-197.
17. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
18. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466.
19. Thom M, Toma A, An S, Martinian L, Hadjivassiliou G, Ratilal B, Dean A, McEvoy A, Sisodiya SM, Brandner S. (2011) One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol 70:859-878.
20. van Breemen MS, Wilms EB, Vecht CJ. (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421-430.
21. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256:1519-1526.
22. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. (2011) Prolonged survival with valproic acid use in the EORTC/ NCIC temozolomide trial for glioblastoma. Neurology 77: 1156-1164.
23. You G, Huang L, Yang P, Zhang W, Yan W, Wang Y, Bao Z, Li S, Li S, Li G, Jiang T. (2012a) Clinical and molecular genetic factors affecting postoperative seizure control of 183 Chinese adult patients with low-grade gliomas. Eur J Neurol 19:298-306.
24. You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, Sang L, Wang Z, Li GL, Li SW, Song YJ, Kang CS, Jiang T. (2012b) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol 14:230-241.
25. Yuen TI, Morokoff AP, Bjorksten A, D'Abaco G, Paradiso L, Finch S, Wong D, Reid CA, Powell KL, Drummond KJ, Rosenthal MA, Kaye AH, O'Brien TJ. (2012) Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology 79:883-889.